Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Short-term Investments (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Short-term Investments data on record, last reported at $178.1 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 13.7% year-over-year to $178.1 million; the TTM value through Dec 2025 reached $178.1 million, up 13.7%, while the annual FY2025 figure was $178.1 million, 13.7% up from the prior year.
  • Short-term Investments reached $178.1 million in Q4 2025 per ARQT's latest filing, up from $143.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $395.4 million in Q3 2022 and bottomed at $118.1 million in Q2 2025.
  • Average Short-term Investments over 5 years is $222.2 million, with a median of $204.7 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: surged 119.08% in 2021, then plummeted 69.74% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $290.6 million in 2021, then increased by 22.48% to $355.9 million in 2022, then crashed by 48.46% to $183.5 million in 2023, then fell by 14.63% to $156.6 million in 2024, then grew by 13.7% to $178.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $178.1 million in Q4 2025, $143.9 million in Q3 2025, and $118.1 million in Q2 2025.